[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 12, 1997

Treatment of Severe Systemic Inflammatory Response Syndrome and Sepsis With a Novel Bradykinin Antagonist, Deltibant (CP-0127)Results of a Randomized, Double-blind, Placebo-Controlled Trial

Author Affiliations

for the CP-0127 SIRS and Sepsis Study Group
From the Winthrop-University Hospital, Mineola, NY (Dr Fein); Vanderbilt University, Nashville, Tenn (Dr Bernard); Temple University Hospital, Philadelphia, Pa (Dr Criner); Houston Veterans Affairs Medical Center, Houston, Tex (Dr Fletcher); University of Louisville Hospital and the Louisville Veterans Affairs Medical Center, Louisville, Ky (Dr Fletcher); Porter and Swedish Hospitals, Denver, Colo (Dr Good); George Washington University, Washington, DC (Dr Knaus); University of New Mexico, Albuquerque (Dr Levy); Saint Louis University Medical Center, St Louis, Mo (Dr Matuschak); Elmhurst Hospital Center, Elmhurst, NY (Dr Shanies); St John's Mercy Medical Center, St Louis, Mo; (Dr Taylor); and Cortech, Inc, Denver, Colo (Dr Rodell).

JAMA. 1997;277(6):482-487. doi:10.1001/jama.1997.03540300050033
Abstract

Objective.  —To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis.

Design.  —Multicenter, randomized, placebo-controlled, double-blind, parallel, dose-ranging trial. Follow-up for 28 days or until death.

Setting.  —A total of 47 US referral hospitals.

Patients.  —A total of 504 patients with SIRS and documented evidence of infection plus either hypotension or dysfunction of 2 organ systems.

Interventions.  —Three-day continuous intravenous infusion of either placebo or 1 of 3 doses (0.3,1.0, or 3.0 μg.kg-1.man-1) of deltibant. Concurrent therapy at the discretion of the treating physician.

Main Outcome Measure.  —Risk-adjusted, 28-day, log-normal intent-to-treat survival analysis. Risk adjustment was performed using a study-specific risk model derived from the APACHE III database.

Results.  —Deltibant had no significant effect on risk-adjusted 28-day survival. In a posthoc analysis, risk-adjusted 7-day survival showed a nonsignificant trend toward improvement (P=.09). The 28-day risk-adjusted survival in the prospectively defined subset of patients with gram-negative infections showed a statistically significant improvement (P=.005).

Conclusions.  —Deltibant may have some effect on survival in patients with SIRS and gram-negative sepsis; however, additional studies would be required to prove this.

×